1. Guidelines Committee. 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.
2. Furberg C.D. Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality hi patients with coronary heart disease. Circulation 1995: 92: l326 31.
3. Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000, 356: 366-72.
4. Major Outcomes High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288; 2981-79.
5. Lindholm L.H., Hansson L., Edhom T. et al. Comparison of antihypertensive treatments treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension J. STOP Hypertension J Study Group. J Hypertens 2000 Nov; 18 (11): 1671.
6. Lombardi F., Terranova P. Hypertension and concurrent arrhythmias. Curr Pharm Des 2003; 9 (21): 1703-13.
7. Weir M.R., Prisant L.M., Papademetrion V. et al. Antihypertensive therapy and quality of life. Influence oj blood pressure reduction, adverse events, and prior antihypertensive therapy Am J Hypertens 1996 Sep: 9 (9): 854-9.
8. Pickering T., James G. Determinants and consequences of the diurnal rhythm of blood pressure. Am J Hypertens Am J Hypertens 1993: 6 (pl. 2): 1665-95.
9. Леонова М.В., Демонова А.В., Малышева Е.А., Белоусов Ю.Б. Влияние антагонистов кальция длительного действия на суточный профиль АД у больных с артериальной гипертонией. Рос. кардиол. Журн. 1999; 3: 36-9.
10. Kyngas H., Lahdenpera Т. Compliance оf patients with hypertension and associated factors. J Adv Nurs 1999: 29: 832-9
11. Ушкалова Е.А. Фармакологические свойства амлодипина-антагониста кальция последнего поколения Фарматека 2004: 14 (91).
12. Gong L., Zhang W.,. Zhu Y. et al. Shanghai Trial of Nifidepine in the Elderly (STONE). J Hypertens 1996: 14: 1237-45.
13. Radaelli A., Bernardi L., Valle F., Leuzzi S. et al. Cardiovascular autonomic modulation in essential hypertension: effect of tilting. Hypertension 1994: 24. 556-63.
14. Chakko S., Mulingtopang R.F. Huikuri H.V. et al. Alternations in heart rate variability audits arcadian rhythm in hypertensive patients with left ventricular hypertrophy free of coronary artery disease. Am Heart J 1993: 126; 1364-72.
15. Langewitz W., Ruddel H., Schacbinger H. Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress. Am Heart J 1994; 127: 122-8.
16. Omvik P., Thaulow E., Herland O.B. et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 1993 Jan; 11 (1): 103-13.
17. Фомина И.Г. Новая форма нифедипина (нифекард XL) в лечении артериальной гипертонии. Клин. фармакол. и тер. 2003; 3.
